Comparison of two medications in central nervous system toxoplasmosis in patients with AIDS

A. Antinori; A. Ammassari; G. Maiuro; G. Camilli; F. Damiano; G. Federico; E. Pizzigallo; E. Tamburrini

doi:10.1007/BF02230867

Comparison of two medications in central nervous system toxoplasmosis in patients with AIDS

A. Antinori, A. Ammassari, G. Maiuro, G. Camilli, F. Damiano, G. Federico, E. Pizzigallo, E. Tamburrini

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

Research output: Contribution to journal › Article › peer-review

Abstract

We retrospectively examined 39 patients with AIDS and central nrvous system toxoplasmosis in order to determine the efficacy and safety of two combinations: pyrimethamine-sulfadiazine and pyrimethamine-clindamycin. The results showed a response rate of 79% for the sulfadiazine association and a high failure rate in the clindamycin group. Side effects with sulfadiazine were slightly more frequent, but with desensitization protocols discontinuation was kept down. The combination of pyrimethamine and sulfadiazine, associated, when necessary, with desensitization schedules, was confirmed to be first choice therapy for cerebral toxoplasmosis in AIDS patients. The role of alternative regimens needs further evaluation.

Original language	English
Pages (from-to)	475-479
Number of pages	5
Journal	Italian Journal of Neurological Sciences
Volume	13
Issue number	6
DOIs	https://doi.org/10.1007/BF02230867
Publication status	Published - Sept 1992

Keywords

pyrimethamine
sulfadiazine
Toxoplasmosis

ASJC Scopus subject areas

Neuroscience(all)
Clinical Neurology

Access to Document

10.1007/BF02230867

Cite this

@article{a8dbd1d9ccc84380b287de520d1109b3,

title = "Comparison of two medications in central nervous system toxoplasmosis in patients with AIDS",

abstract = "We retrospectively examined 39 patients with AIDS and central nrvous system toxoplasmosis in order to determine the efficacy and safety of two combinations: pyrimethamine-sulfadiazine and pyrimethamine-clindamycin. The results showed a response rate of 79% for the sulfadiazine association and a high failure rate in the clindamycin group. Side effects with sulfadiazine were slightly more frequent, but with desensitization protocols discontinuation was kept down. The combination of pyrimethamine and sulfadiazine, associated, when necessary, with desensitization schedules, was confirmed to be first choice therapy for cerebral toxoplasmosis in AIDS patients. The role of alternative regimens needs further evaluation.",

keywords = "pyrimethamine, sulfadiazine, Toxoplasmosis",

author = "A. Antinori and A. Ammassari and G. Maiuro and G. Camilli and F. Damiano and G. Federico and E. Pizzigallo and E. Tamburrini",

year = "1992",

month = sep,

doi = "10.1007/BF02230867",

language = "English",

volume = "13",

pages = "475--479",

journal = "Italian Journal of Neurological Sciences",

issn = "0392-0461",

publisher = "Springer Verlag",

number = "6",

}

TY - JOUR

T1 - Comparison of two medications in central nervous system toxoplasmosis in patients with AIDS

AU - Antinori, A.

AU - Ammassari, A.

AU - Maiuro, G.

AU - Camilli, G.

AU - Damiano, F.

AU - Federico, G.

AU - Pizzigallo, E.

AU - Tamburrini, E.

PY - 1992/9

Y1 - 1992/9

N2 - We retrospectively examined 39 patients with AIDS and central nrvous system toxoplasmosis in order to determine the efficacy and safety of two combinations: pyrimethamine-sulfadiazine and pyrimethamine-clindamycin. The results showed a response rate of 79% for the sulfadiazine association and a high failure rate in the clindamycin group. Side effects with sulfadiazine were slightly more frequent, but with desensitization protocols discontinuation was kept down. The combination of pyrimethamine and sulfadiazine, associated, when necessary, with desensitization schedules, was confirmed to be first choice therapy for cerebral toxoplasmosis in AIDS patients. The role of alternative regimens needs further evaluation.

AB - We retrospectively examined 39 patients with AIDS and central nrvous system toxoplasmosis in order to determine the efficacy and safety of two combinations: pyrimethamine-sulfadiazine and pyrimethamine-clindamycin. The results showed a response rate of 79% for the sulfadiazine association and a high failure rate in the clindamycin group. Side effects with sulfadiazine were slightly more frequent, but with desensitization protocols discontinuation was kept down. The combination of pyrimethamine and sulfadiazine, associated, when necessary, with desensitization schedules, was confirmed to be first choice therapy for cerebral toxoplasmosis in AIDS patients. The role of alternative regimens needs further evaluation.

KW - pyrimethamine

KW - sulfadiazine

KW - Toxoplasmosis

UR - http://www.scopus.com/inward/record.url?scp=0026806589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026806589&partnerID=8YFLogxK

U2 - 10.1007/BF02230867

DO - 10.1007/BF02230867

M3 - Article

C2 - 1428784

AN - SCOPUS:0026806589

SN - 0392-0461

VL - 13

SP - 475

EP - 479

JO - Italian Journal of Neurological Sciences

JF - Italian Journal of Neurological Sciences

IS - 6

ER -

Comparison of two medications in central nervous system toxoplasmosis in patients with AIDS

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this